# US 2005/0232973 A1 · Systems and methods for preparation of pharmaceutical dosage using compositions containing aqueous vesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232973 A1
- Document ID: US20050232973A1
- Status: Published application
- Kind: A1
- Application number: 10/827,484
- Filed: 2004-04-19
- Published: 2005-10-20
- Earliest claimed: 2004-04-19
- Inventors: Makarand Gore
- Web page: https://patentgrep.com/patent/US20050232973A1

## CPC

- C09D 11/30: Inkjet printing inks
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/1277: Preparation processes; Proliposomes
- C09D: COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR (cosmetics A61K; processes for applying liquids or other fluent materials to surfaces, in general, B05D; staining wood B27K5/02; glazes or vitreous enamels C03C; natural resins, French polish, drying-oils, driers, turpentine, per se, C09F; polishing compositions other than French polish, ski waxes C09G; adhesives or use of materials as adhesives C09J; materials for sealing or packing joints or covers C09K3/10; materials for stopping leaks C09K3/12; processes for the electrolytic or electrophoretic production of coatings C25D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A jettable solution includes a plurality of vesicles, and a pharmaceutical payload associated with the vesicles.

## Claims

### Claim 1

A jettable solution comprising:
a plurality of vesicles; and
a pharmaceutical payload associated with said vesicles.

### Claim 2 (depends on 1)

The jettable solution of claim 1, wherein said jettable solution further comprises an edible vehicle, said plurality of vesicles being stably dispersed in said edible vehicle.

### Claim 3 (depends on 2)

The jettable solution of claim 2, wherein said edible vehicle comprises one of water or an alcohol.

### Claim 4 (depends on 3)

The jettable solution of claim 3, wherein sad edible vehicle further comprises a solvent.

### Claim 5 (depends on 1)

The jettable solution of claim 1, wherein said plurality of vesicles are formed from a lipid or a mixture of lipids selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acids, phosphatidylserines, phosphatidylglycerols, cardiolipins, poly(ethylene glycol) lipid conjugates, sphingomyelins, cationic lipids, trioctanoin, triolein, dioctanoyl glycerol, cholesterol (ovine wool), lipid A (salmonella minnesota), purified lipid A, and dioleoyl-glutaric acid.

### Claim 6 (depends on 1)

The jettable solution of claim 1, wherein said plurality of vesicles are formed from a plurality of di-block copolymers.

### Claim 7 (depends on 1)

The jettable solution of claim 1, wherein said plurality of vesicles comprise dimensions of less than 10 microns.

### Claim 8 (depends on 1)

The jettable solution of claim 1, wherein said pharmaceutical payload comprises a substantially water-insoluble pharmaceutical.

### Claim 9 (depends on 8)

The jettable solution of claim 8, wherein said pharmaceutical payload is selected from the group consisting of Quinidex, Procainamide, Verapamil, Nitroglycerin, Quinidine, Calan, Disopyramide, Sotalol, Mexitil, Pindolol, Isosorbide 5-mononitrate, Cordarone, Digoxin, Nifedipine, Timolol, Dihydropyridine, Ethmozine, Rythmol, Acebutolol, Penbutolol, Nadolol, Diltiazem, Carteolol, Tambocor, Nicardipine, Captopril, Bepridil, Felodipine, Isradipine, Enalapril, Vasotec, Enalaprilat, Zestril, Esmolol, Univasc, Accupril, Quinapril, Lotensin, Benazepril, Altace, Trandolapril, Amlodipine, Monopril, Fosinopril, Moexipril, and Corvert.

### Claim 10 (depends on 1)

The jettable solution of claim 1, further comprising a property enhancing agent.

### Claim 11 (depends on 10)

The jettable solution of claim 10, wherein said property enhancing agent comprises one of a biocide, a viscosity modifier, a humectant, an antifoaming agent, a surface tension adjusting agent, a rheology adjusting agent, a pH adjusting agent, a drying agent, or a polymer.

### Claim 12 (depends on 1)

The jettable solution of claim 1, wherein said solution comprises a viscosity of less than 5 centipoise.

### Claim 13 (depends on 1)

The jettable solution of claim 1, wherein said solution comprises a surface tension between approximately 25 and 60 dynes per centimeter.

### Claim 14 (depends on 1)

The jettable solution of claim 1, wherein said solution is configured to be selectively emitted from an inkjet material dispenser.

### Claim 15 (depends on 14)

The jettable solution of claim 14, wherein said inkjet material dispenser comprises one of a thermally actuated inkjet dispenser, a mechanically actuated inkjet dispenser, an electro-statically actuated inkjet dispenser, a magnetically actuated dispenser, a piezo-electrically actuated inkjet dispenser, or a continuous inkjet dispenser.

### Claim 16 (depends on 1)

The jettable solution of claim 1, further comprising:
approximately 25% vehicle;
approximately 2% vesicle forming component;
approximately 3 to 6% pharmaceutical payload; and
water.

### Claim 17 (depends on 1)

The jettable solution of claim 1, further comprising:
approximately 3.54% vitamin E-succinate;
approximately 0.8% Tris;
approximately 75.64% water; and
approximately 20% Diethylene glycol.

### Claim 18 (depends on 1)

The jettable solution of claim 1, further comprising:
approximately 5% 1,3propanediol;
approximately 3% Brij30;
approximately 0.15% hexadecyltrimethylammonium bromide (HTAB);
approximately 1% Cholesterol;
between 5 and 10% pharmaceutical payload; and
water.

### Claim 19 (depends on 1)

The jettable solution of claim 1, further comprising:
approximately 2.5% egg yolk or Phosphotidyl choline Soy Lecithin;
approximately 1.0% Cholic acid Na salt;
approximately 5% Diethylene glycol;
approximately 5% pharmaceutical payload; and
water.

### Claim 20 (depends on 1)

The jettable solution of claim 1, further comprising:
approximately 5% sucrosemono/di stearate;
approximately 5% 1,3 propane diol;
approximately 5% pharmaceutical payload; and
water.

### Claim 21

A method for forming a jettable pharmaceutical solution comprising:
presenting a pharmaceutical combining said pharmaceutical with a vesicle forming material and an aqueous vehicle; and
processing said combination to form a jettable solution including a plurality of vesicles containing said pharmaceutical.

### Claim 22 (depends on 21)

The method of claim 21, further comprising grinding said pharmaceutical to a particle size of less than 200 nanometers.

### Claim 23 (depends on 22)

The method of claim 22, wherein said grinding further comprises processing said pharmaceutical with a microfluidizer.

### Claim 24 (depends on 21)

The method of claim 21, wherein said pharmaceutical comprises a substantially water insoluble pharmaceutical.

### Claim 25 (depends on 21)

The method of claim 21, wherein said pharmaceutical is selected from the group consisting of Quinidex, Procainamide, Verapamil, Nitroglycerin, Quinidine, Calan, Disopyramide, Sotalol, Mexitil, Pindolol, Isosorbide 5-mononitrate, Cordarone, Digoxin, Nifedipine, Timolol, Dihydropyridine, Ethmozine, Rythmol, Acebutolol, Penbutolol, Nadolol, Diltiazem, Carteolol, Tambocor, Nicardipine, Captopril, Bepridil, Felodipine, Isradipine, Enalapril, Vasotec, Enalaprilat, Zestril, Esmolol, Univasc, Accupril, Quinapril, Lotensin, Benazepril, Altace, Trandolapril, Amlodipine, Monopril, Fosinopril, Moexipril, and Corvert.

### Claim 26 (depends on 21)

The method of claim 21, wherein said vesicle forming material comprises a plurality of lipids.

### Claim 27 (depends on 26)

The method of claim 26, wherein said plurality of lipids are selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acids, phosphatidylserines, phosphatidylglycerols, cardiolipins, poly(ethylene glycol) lipid conjugates, sphingomyelins, cationic lipids, trioctanoin, triolein, dioctanoyl glycerol, cholesterol (ovine wool), lipid A (salmonella minnesota), purified lipid A, and dioleoyl-glutaric acid.

### Claim 28 (depends on 21)

The method of claim 21, wherein said vesicle forming material comprises a plurality of di-block copolymers.

### Claim 29 (depends on 28)

The method of claim 28, wherein said di-block copolymers comprise polylethyleneoxide-polyethylethylene.

### Claim 30 (depends on 21)

The method of claim 21, wherein said aqueous vehicle comprises one of water or an alcohol.

### Claim 31 (depends on 30)

The method of claim 30, wherein said aqueous vehicle further comprises a solvent.

### Claim 32 (depends on 21)

The method of claim 21, wherein said combining said pharmaceutical with a vesicle forming material and an aqueous vehicle comprises mixing said pharmaceutical, said vesicle forming material, and said aqueous vehicle.

### Claim 33 (depends on 21)

The method of claim 21, wherein said processing said combination to form a jettable solution including a plurality of vesicles containing said pharmaceutical comprises performing one of a mechanical dispersion process, a micro-emulsification process, a sonication process, a membrane extrusion process, a microfluidization process, or an acute pressure valve homogenization (APV) process.

### Claim 34 (depends on 33)

The method of claim 33, wherein said APV homogenization process comprises:
forcing said combination through a valve having a small orifice and an impact ring.

### Claim 35 (depends on 21)

The method of claim 21, wherein said jettable solution is configured to be selectively emitted from an inkjet material dispenser.

### Claim 36 (depends on 35)

The method of claim 35, wherein said inkjet material dispenser comprises one of a thermally actuated inkjet dispenser, a mechanically actuated inkjet dispenser, an electro-statically actuated inkjet dispenser, a magnetically actuated dispenser, a piezo-electrically actuated inkjet dispenser, or a continuous inkjet dispenser.

### Claim 37 (depends on 21)

The method of claim 21, wherein said plurality of vesicles comprise a dimension of less than 10 microns.

### Claim 38 (depends on 37)

The method of claim 37, wherein said jettable solution comprises a viscosity of less than 5 centipoise.

### Claim 39 (depends on 37)

The method of claim 37, wherein said jettable solution comprises a surface tension between approximately 25 and 60 dynes per centimeter.

### Claim 40 (depends on 21)

The method of claim 21, further comprising dispensing a property enhancing agent into said combination.

### Claim 41 (depends on 40)

The method of claim 40, wherein said property enhancing agent comprises one of a biocide, a viscosity modifier, a humectant, an antifoaming agent, a surface tension adjusting agent, a rheology adjusting agent, a pH adjusting agent, a drying agent, or a polymer.

### Claim 42

A method for forming an oral pharmaceutical comprising:
presenting an edible structure adjacent to an inkjet material dispenser; and
selectively dispensing an aqueous vesicle pharmaceutical from said inkjet material dispenser onto said edible structure.

### Claim 43 (depends on 42)

The method of claim 42, wherein said inkjet material dispenser comprises one of a thermally actuated inkjet dispenser, a mechanically actuated inkjet dispenser, an electrostatically actuated inkjet dispenser, a magnetically actuated dispenser, a piezo-electrically actuated inkjet dispenser, or a continuous inkjet dispenser.

### Claim 44 (depends on 42)

The method of claim 42, wherein said selectively dispensing comprises dispensing a predetermined dosage of said aqueous vesicle pharmaceutical.

### Claim 45 (depends on 42)

The method of claim 42, wherein said edible structure comprises one of a polymeric or paper organic film former.

### Claim 46 (depends on 42)

The method of claim 42, wherein said aqueous vesicle pharmaceutical comprises a pharmaceutical payload enclosed within a liposome vesicle.

### Claim 47 (depends on 42)

The method of claim 42, further comprising dividing said edible structure into a plurality of single oral doses.

### Claim 48 (depends on 42)

The method of claim 42, further comprising selectively dispensing a plurality of aqueous vesicle pharmaceuticals onto said edible structure, said plurality of aqueous pharmaceuticals forming a combination therapy.

### Claim 49

A system for dispensing an oral solution comprising:
an edible structure; and
a vesicle solution containing a pharmaceutical payload configured to be dispensed onto said edible structure.

### Claim 50 (depends on 49)

The system of claim 49, wherein said edible structure comprises one of a rice starch based paper, a potato starch based paper, or an edible polymer.

### Claim 51 (depends on 49)

The system of claim 49, wherein said vesicle solution comprises vesicles formed from one of a liposome or a polymersome.

### Claim 52 (depends on 49)

The system of claim 49, further comprising:
a computing device disposed adjacent to said edible structure;
an inkjet material dispenser communicatively coupled to said computing device; and
a material reservoir fluidly coupled to said inkjet material dispenser, said material reservoir being configured to supply said liposome vesicle solution containing a pharmaceutical payload to said inkjet material dispenser.

### Claim 53 (depends on 52)

The system of claim 52, wherein said computing device comprises one of a personal computer, a laptop computer, a personal digital assistant, or a cellular telephone.

### Claim 54 (depends on 52)

The system of claim 52, wherein said inkjet material dispenser comprises one of a thermally actuated inkjet dispenser, a mechanically actuated inkjet dispenser, an electrostatically actuated inkjet dispenser, a magnetically actuated dispenser, a piezo-electrically actuated inkjet dispenser, or a continuous inkjet dispenser.

### Claim 55

A jettable solution comprising:
a water insoluble pharmaceutical payload; and
a means for encapsulating said pharmaceutical payload into a jettable solution.

### Claim 56 (depends on 55)

The jettable solution of claim 55, wherein said jettable solution further comprises a means for stably dispersing said encapsulated pharmaceutical payload.

### Claim 57

A system for dispensing an oral solution comprising:
an edible means for receiving a pharmaceutical payload solution; and
a liposome vesicle solution containing a pharmaceutical payload configured to be dispensed onto said means for receiving a pharmaceutical payload solution.

### Claim 58 (depends on 57)

The system of claim 57, wherein said edible means for receiving a pharmaceutical payload solution comprises one of a rice starch based paper, a potato starch based paper, or an edible polymer.

### Claim 59 (depends on 58)

The system of claim 58, further comprising:
a means for computing disposed adjacent to said edible structure;
a means for selectively dispensing said pharmaceutical payload solution communicatively coupled to said means for computing; and
a material reservoir fluidly coupled to said means for selectively dispensing said pharmaceutical payload solution, said material reservoir being configured to supply said pharmaceutical payload solution to said inkjet material dispenser.
